↓ Skip to main content

Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort

Overview of attention for article published in The Lancet Respiratory Medicine, June 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
3 news outlets
policy
2 policy sources
twitter
59 X users
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
234 Dimensions

Readers on

mendeley
179 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort
Published in
The Lancet Respiratory Medicine, June 2017
DOI 10.1016/s2213-2600(17)30207-2
Pubmed ID
Authors

MeiLan K Han, Pedro M Quibrera, Elizabeth E Carretta, R Graham Barr, Eugene R Bleecker, Russell P Bowler, Christopher B Cooper, Alejandro Comellas, David J Couper, Jeffrey L Curtis, Gerard Criner, Mark T Dransfield, Nadia N Hansel, Eric A Hoffman, Richard E Kanner, Jerry A Krishnan, Carlos H Martinez, Cheryl B Pirozzi, Wanda K O'Neal, Stephen Rennard, Donald P Tashkin, Jadwiga A Wedzicha, Prescott Woodruff, Robert Paine, Fernando J Martinez, SPIROMICS investigators, Neil E Alexis, Wayne H Anderson, R Graham Barr, Eugene R Bleecker, Richard C Boucher, Russell P Bowler, Elizabeth E Carretta, Stephanie A Christenson, Alejandro P Comellas, Christopher B Cooper, David J Couper, Gerard J Criner, Ronald G Crystal, Jeffrey L Curtis, Claire M Doerschuk, Mark T Dransfield, Christine M Freeman, MeiLan K Han, Nadia N Hansel, Annette T Hastie, Eric A Hoffman, Robert J Kaner, Richard E Kanner, Eric C Kleerup, Jerry A Krishnan, Lisa M LaVange, Stephen C Lazarus, Fernando J Martinez, Deborah A Meyers, John D Newell, Elizabeth C Oelsner, Wanda K O'Neal, Robert Paine, Nirupama Putcha, Stephen I. Rennard, Donald P Tashkin, Mary Beth Scholand, J Michael Wells, Robert A Wise, Prescott G Woodruff

Abstract

Present treatment strategies to stratify exacerbation risk in patients with chronic obstructive pulmonary disease (COPD) rely on a history of two or more events in the previous year. We aimed to understand year to year variability in exacerbations and factors associated with consistent exacerbations over time. In this longitudinal, prospective analysis of exacerbations in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort, we analysed patients aged 40-80 years with COPD for whom 3 years of prospective data were available, identified through various means including care at academic and non-academic medical centres, word of mouth, and existing patient registries. Participants were enrolled in the study between Nov 12, 2010, and July 31, 2015. We classified patients according to yearly exacerbation frequency: no exacerbations in any year; one exacerbation in every year during 3 years of follow-up; and those with inconsistent exacerbations (individuals who had both years with exacerbations and years without during the 3 years of follow-up). Participants were characterised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric category (1-4) on the basis of post-bronchodilator FEV1. Stepwise logistic regression was used to compare factors associated with one or more acute exacerbations of COPD every year for 3 years versus no exacerbations in the same timeframe. Additionally, a stepwise zero-inflated negative binomial model was used to assess predictors of exacerbation count during follow-up in all patients with available data. Baseline symptom burden was assessed with the COPD assessment test. This trial is registered with ClinicalTrials.gov, number NCT01969344. 2981 patients were enrolled during the study. 1843 patients had COPD, of which 1105 patients had 3 years of complete, prospective follow-up data. 538 (49%) of 1105 patients had at least one acute exacerbation during the 3 years of follow-up, whereas 567 (51%) had none. 82 (7%) of 1105 patients had at least one acute exacerbation each year, whereas only 23 (2%) had two or more acute exacerbations in each year. An inconsistent pattern (both years with and without acute exacerbations) was common (456 [41%] of the group), particularly among GOLD stages 3 and 4 patients (256 [56%] of 456). In logistic regression, consistent acute exacerbations (≥1 event per year for 3 years) were associated with higher baseline symptom burden, previous exacerbations, greater evidence of small airway abnormality on CT, lower interleukin-15 concentrations, and higher interleukin-8 concentrations, than were no acute exacerbations. Although acute exacerbations are common, the exacerbation status of most individuals varies markedly from year to year. Among patients who had any acute exacerbation over 3 years, very few repeatedly had two or more events per year. In addition to symptoms and history of exacerbations in the year before study enrolment, we identified several novel biomarkers associated with consistent exacerbations, including CT-defined small airway abnormality, and interleukin-15 and interleukin-8 concentrations. National Institutes of Health, and National Heart, Lung, and Blood Institute.

X Demographics

X Demographics

The data shown below were collected from the profiles of 59 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 179 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 179 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 25 14%
Student > Master 22 12%
Other 20 11%
Student > Ph. D. Student 19 11%
Student > Postgraduate 12 7%
Other 48 27%
Unknown 33 18%
Readers by discipline Count As %
Medicine and Dentistry 76 42%
Pharmacology, Toxicology and Pharmaceutical Science 13 7%
Agricultural and Biological Sciences 11 6%
Nursing and Health Professions 9 5%
Biochemistry, Genetics and Molecular Biology 9 5%
Other 22 12%
Unknown 39 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 67. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2022.
All research outputs
#642,641
of 25,584,565 outputs
Outputs from The Lancet Respiratory Medicine
#456
of 2,887 outputs
Outputs of similar age
#13,420
of 328,855 outputs
Outputs of similar age from The Lancet Respiratory Medicine
#6
of 64 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,887 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 78.8. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,855 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.